PubMed:19891556 / 960-1149 JSONTXT

{"project":"LitCoin-entities","denotations":[{"id":"6785","span":{"begin":93,"end":100},"obj":"GeneOrGeneProduct"},{"id":"6786","span":{"begin":159,"end":170},"obj":"ChemicalEntity"}],"attributes":[{"id":"A13","pred":"db_id","subj":"6785","obj":"NCBIGene:1557"},{"id":"A14","pred":"db_id","subj":"6786","obj":"MESH:D000077144"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"Future studies remain necessary to develop effective personalized therapeutic strategies for CYP2C19 variant allele carriers and other individuals at risk for clopidogrel nonresponsiveness."}

{"project":"LitCoin-sentences","denotations":[{"id":"T7","span":{"begin":0,"end":189},"obj":"Sentence"}],"text":"Future studies remain necessary to develop effective personalized therapeutic strategies for CYP2C19 variant allele carriers and other individuals at risk for clopidogrel nonresponsiveness."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T11","span":{"begin":93,"end":100},"obj":"GeneOrGeneProduct"},{"id":"T12","span":{"begin":116,"end":124},"obj":"GeneOrGeneProduct"},{"id":"T13","span":{"begin":129,"end":134},"obj":"GeneOrGeneProduct"}],"text":"Future studies remain necessary to develop effective personalized therapeutic strategies for CYP2C19 variant allele carriers and other individuals at risk for clopidogrel nonresponsiveness."}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T5","span":{"begin":93,"end":100},"obj":"GeneOrGeneProduct"},{"id":"T6","span":{"begin":129,"end":134},"obj":"GeneOrGeneProduct"}],"text":"Future studies remain necessary to develop effective personalized therapeutic strategies for CYP2C19 variant allele carriers and other individuals at risk for clopidogrel nonresponsiveness."}

{"project":"LitCoin-GeneOrGeneProduct-v3","denotations":[{"id":"T4","span":{"begin":93,"end":100},"obj":"GeneOrGeneProduct"}],"text":"Future studies remain necessary to develop effective personalized therapeutic strategies for CYP2C19 variant allele carriers and other individuals at risk for clopidogrel nonresponsiveness."}

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T16","span":{"begin":159,"end":170},"obj":"ChemicalEntity"}],"attributes":[{"id":"A16","pred":"ID:","subj":"T16","obj":"D000077144"},{"id":"A17","pred":"ID:","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_37941"},{"id":"A18","pred":"ID:","subj":"T16","obj":"ChemicalEntity"}],"text":"Future studies remain necessary to develop effective personalized therapeutic strategies for CYP2C19 variant allele carriers and other individuals at risk for clopidogrel nonresponsiveness."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T16","span":{"begin":159,"end":170},"obj":"ChemicalEntity"},{"id":"T39688","span":{"begin":93,"end":100},"obj":"GeneOrGeneProduct"}],"attributes":[{"id":"A18","pred":"ID:","subj":"T16","obj":"ChemicalEntity"},{"id":"A17","pred":"ID:","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_37941"},{"id":"A16","pred":"ID:","subj":"T16","obj":"D000077144"}],"text":"Future studies remain necessary to develop effective personalized therapeutic strategies for CYP2C19 variant allele carriers and other individuals at risk for clopidogrel nonresponsiveness."}